drugset / Trial / NCT02784002
A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this research study is to evaluate the safety and effectiveness of Ridinilazole (SMT19969) in treating C. difficile Infection (CDI).
Timeline
- Start
- 2014-12
- Primary completion
- 2016-08
- Completion
- 2016-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Fidaxomicin | Other / unclassified | 200 mg | — |
| Subject | Ridinilazole | Small molecule | 200 mg | — |